Glaxo's Lung Drug Anoro Recommended by Europe Regulator
This article is for subscribers only.
GlaxoSmithKline Plc said the lung drug Anoro, a follow-up medicine to its best-selling Advair, was recommended for approval by Europe’s drug regulator.
Anoro was recommended by the European Medicines Agency as a once-daily treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease, the London-based company said in a statement today. The drug was approved in the U.S. in December.